TDC treatment for advanced non-squamous lung cancer
Part of Brain & nervous system, Cancer, Genetic & congenital, Lungs & breathing clinical trials.
This study is looking at how well a new treatment called TDC (which includes durvalumab and chemotherapy) works for people with a certain type of advanced lung cancer that has spread and has specific genetic features. It aims to see if this treatment is effective and safe in the real world, and it might be an option if you are starting this therapy anyway.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and able to give consent.
- You have been diagnosed with a type of lung cancer that is not squamous (or a special type called LCNEC that is treated like it).
- Your cancer has spread to other parts of the body (metastatic).
- Your doctor has decided to start you on a first-line treatment that includes durvalumab and a chemotherapy combination called TDC.
- Your tumor does NOT have certain specific genetic changes (EGFR mutations or ALK rearrangements).
- You are not currently in another interventional clinical trial, and you don't have any other active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
This trial tests whether adding two drugs, durvalumab and ceralasertib, after radiotherapy can help patients with stage III non-small cell lung cancer whose cancer has come back in the chest or spread to a few other spots after previous treatment with durvalumab. It aims to improve outcomes by boosting the immune system's ability to fight the cancer.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Hear when a new Non-squamous Metastatic Non-Small-Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.